You are here: Industry Insights > Silence Therapeutics

News List

AstraZeneca, Silence Therapeutics Announce siRNA Collaboration americanpharmaceuticalreview
March 31, 2020
AstraZeneca will collaborate with Silence Therapeutics to discover, develop and commercialize small interfering RNA (siRNA) therapeutics for the treatment of Cardiovascular, Renal, Metabolic and Respiratory diseases.
AstraZeneca and Silence Therapeutics sign drug development deal pharmaceutical-technology
March 27, 2020
AstraZeneca has partnered with Silence Therapeutics for the discovery, development and commercialisation of small interfering RNA (siRNA) drugs for cardiovascular, renal, metabolic and respiratory diseases.
AZ to develop siRNA with Silence Theraputics pharmatimes
March 26, 2020
AstraZeneca has revealed plans to collaborate with Silence Therapeutics to discover, develop and commercialise small interfering RNA (siRNA) therapeutics for the treatment of cardiovascular, renal, metabolic and respiratory diseases.
Mallinckrodt partners with Silence Therapeutics for RNAi drugs pharmaceutical-technology
July 22, 2019
Mallinckrodt has partnered with Silence Therapeutics for the development and commercialisation of RNA interference (RNAi) drugs to treat patients with complement-mediated diseases.
Mallinckrodt, Silence Therapeutics Announce Collaboration americanpharmaceuticalreview
July 19, 2019
Mallinckrodt and Silence Therapeutics announced a collaboration that will allow the companies to develop and commercialize RNAi drug targets designed to inhibit or 'silence' the complement cascade ...
Silence Therapeutics takes rival Alnylam to court in patent fight pharmaphorum
July 05, 2017
Silence Therapeutics has launched legal action alleging that late stage drugs from rivals Alnylam and The Medicines Company infringe its intellectual property.